SOURCE: InDevR, Inc.

InDevR - Inspired Life Science Technology

November 12, 2013 08:00 ET

InDevR Launches miPLEX™ to Transition Immunoassays Into Powerful Multiplexed Platform

BOULDER, CO--(Marketwired - November 12, 2013) - InDevR Inc., a Boulder-based biotechnology company announces a new product portfolio, miPLEX™, that enables businesses to upgrade traditional immunoassays to a time- and cost-saving multiplexed platform.

The miPLEX product line is a unique combination of service, consumables, and instrumentation. InDevR's scientists work with target-specific reagents provided by partner companies to translate single-well immunoassays into a highly multiplexed platform. In general, miPLEX uses 1000 times less immuno-reagent than ELISA thereby reducing the cost of goods. "Customer surveys have shown that the major points of dissatisfaction with ELISA-like assays are reagent consumption, limited throughput, and poor precision. The miPLEX platform provides cost-effective solutions to each of those problems", said Dr. Kathy Rowlen, InDevR's CEO. "Reducing production costs for our B2B customers will improve their margin and the multiplexed, high throughput platform will translate into time savings for the end customer -- definitely a win-win proposition," she said. 

As part of the miPLEX platform, InDevR is also launching a new fluorescence microarray imaging system, Vidia™, as a complement to its ampliPHOX® colorimetric imaging system. Vidia has extraordinary versatility and works with both glass slides and microwell plates. Designed as a true imaging system, Vidia performs quantitative analysis 10 times faster than other commercially available scanners or readers.

InDevR is actively seeking collaboration with biological reagent providers interested in differentiating their products from the competition. Corgenix Medical Corporation (OTCBB: CONX), a Colorado company that provides state-of-the-art solutions for the medical diagnostic industry, is capitalizing on a pilot study program at InDevR. According to Douglass Simpson, President and CEO of Corgenix "We are enthusiastic about working with InDevR to evaluate the miPLEX platform. The potential to provide a superior product to our customers while reducing our costs is highly appealing."

About InDevR
InDevR's mission is to develop and deliver revolutionary analytical tools for detection and characterization of biological molecules and microorganisms. Founded in 2003 by three scientists, InDevR has attracted talented business personnel, engineers, and scientists to address critical unmet needs in fields ranging from vaccine development to pathogen detection. With 10 years experience in innovation, product development, manufacturing, and product sales for the life science industry, InDevR has a keen understanding of how to translate great ideas into impactful products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.

About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Image Available: http://www.marketwire.com/library/MwGo/2013/11/11/11G009881/Images/Vidia_Logo_FNL-Tagline-255492511742.jpg

Contact Information